| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Arcellx, Inc. | Director | Common Stock | 2,095,114 | $115,792,551 | $55.27 | 08 Feb 2022 | Indirect |
| Protagonist Therapeutics, Inc | Director | Common Stock | 7,825 | $683,433 | $87.34 | 02 Jan 2026 | Direct |
| Neoleukin Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25,000 | 11 May 2021 | Direct | ||
| Protagonist Therapeutics, Inc | Director | Stock Option (right to buy) | 3,762 | 02 Jan 2026 | Direct | ||
| Arcellx, Inc. | Director | Series B-1 Preferred Stock | 0 | 08 Feb 2022 | Indirect | ||
| Arcellx, Inc. | Director | Series B-2 Preferred Stock | 0 | 08 Feb 2022 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | 02 Jan 2026 | 2 | $0 | 4 | Director | 06 Jan 2026, 19:40 |
| PTGX | Protagonist Therapeutics, Inc | 02 Jan 2025 | 2 | $0 | 4 | Director | 06 Jan 2025, 18:09 |
| PTGX | Protagonist Therapeutics, Inc | 02 Jan 2024 | 1 | $0 | 4 | Director | 04 Jan 2024, 20:14 |
| PTGX | Protagonist Therapeutics, Inc | 16 Jan 2023 | 1 | $0 | 4 | Director | 18 Jan 2023, 19:10 |
| PTGX | Protagonist Therapeutics, Inc | 26 May 2022 | 1 | $0 | 4 | Director | 27 May 2022, 16:01 |
| ACLX | Arcellx, Inc. | 08 Feb 2022 | 3 | $0 | 4 | Director | 09 Feb 2022, 16:54 |
| ACLX | Arcellx, Inc. | 03 Feb 2022 | 0 | $0 | 3 | Director | 03 Feb 2022, 16:26 |
| PTGX | Protagonist Therapeutics, Inc | 27 May 2021 | 1 | $0 | 4 | Director | 28 May 2021, 19:06 |
| NGNE | Neoleukin Therapeutics, Inc. | 11 May 2021 | 1 | $0 | 4 | Director | 13 May 2021, 17:39 |